Floatz Rating
B57/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04128501CT.gov Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | — | Active Not Recruiting | — | — | — |
NCT03683433CT.gov Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | — | Recruiting | — | — | — |
NCT02397720CT.gov Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bilineal Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Azacitidine (this asset) | M.D. Anderson Cancer Center | P2 | B · 57 |
| Nivolumab | M.D. Anderson Cancer Center | P2 | B |
| Rituximab | M.D. Anderson Cancer Center | P2 | B |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P2 | B |
| Sorafenib | M.D. Anderson Cancer Center | P2 | B |
| Dexasone | M.D. Anderson Cancer Center | P2 | B |
| Idarubicin | M.D. Anderson Cancer Center | P2 | B |
| Cytarabine | M.D. Anderson Cancer Center | P2 | B |
| Clofarabine | M.D. Anderson Cancer Center | P2 | B |
+6 more in the Bilineal Acute Myeloid Leukemia cohort
Other indications for Azacitidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 73 |
| Acute Erythroid Leukemia | — | P2 | BB · 71 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Azacitidine in Bilineal Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/azacitidine-bilineal-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →